What is the current Global Hereditary Angioedema Therapeutics Market size?

The Global Hereditary Angioedema Therapeutics Market is projected to register a CAGR of 8.5% during the forecast period (2024-2029) Read More

Who are the key players in Global Hereditary Angioedema Therapeutics Market?

CSL Behring, Takeda Pharmaceutical Company Limited, Pharming Healthcare Inc., Sanofi and BioCryst Pharmaceuticals Inc. are the major companies operating in the Global Hereditary Angioedema Therapeutics Market. Read More

Which is the fastest growing region in Global Hereditary Angioedema Therapeutics Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Global Hereditary Angioedema Therapeutics Market?

In 2024, the North America accounts for the largest market share in Global Hereditary Angioedema Therapeutics Market. Read More

What years does this Global Hereditary Angioedema Therapeutics Market cover?

The report covers the Global Hereditary Angioedema Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Hereditary Angioedema Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Global Hereditary Angioedema Therapeutics Market Share

Statistics for the 2023 & 2024 Global Hereditary Angioedema Therapeutics market share, created by Mordor Intelligence™ Industry Reports. Global Hereditary Angioedema Therapeutics share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Global Hereditary Angioedema Therapeutics Industry

The hereditary angioedema therapeutics market is highly consolidated in terms of competition and consists of limited major players. Some of the companies currently dominating the market are CSL Behring, Takeda Pharmaceutical Company Limited, Pharming Healthcare Inc., BioCryst Pharmaceuticals Inc., Attune Pharmaceuticals Inc., Ionis Pharmaceuticals, KalVista Pharmaceuticals Inc., and Adverum Biotechnologies Inc.